We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the pdf to learn about:
1. Three agents with the potential to reach the market this year for weight loss, nonalcoholic steatohepatitis (NASH), and melanoma.
2. Other significant treatments expected in the next few years, including gene therapies and biosimilars, and a spotlight on the pipeline for dry eye disease.
3. The emerging area of digital therapeutics, and psychedelic agents in development for treatment of diseases such as depression and post-traumatic stress disorder (PTSD).
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.